Marc Ferrante

62PUBLICATIONS
147CO-AUTHORS
Immunogenetics (incl. genetic immunology)PharmacogenomicsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Food properties (incl. characteristics and health benefits)Cancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (62)

|Jul 23, 2026
Patient Preferences for Inflammatory Bowel Disease Treatment: Results from a Global Survey Conducted in Partnership with the European Federation of Crohn's & Ulcerative Colitis Associations.

|Apr 08, 2026
Why the Assay Matters in Model-Informed Precision Dosing: An Example of Ustekinumab in Crohn's Disease.

Wei Zhang, Zhigang Wang, Thierry Dervieux

|Mar 24, 2026
Personalized infliximab rescue therapy to maximize colectomy-free survival in patients with acute severe ulcerative colitis.

Emmanuel Niyigena, Yannick Hoffert, Waqqas Afif

|Dec 23, 2025
Multi-stakeholder validation of an evidence-based core set of quality indicators for IBD in Belgium.

Liselotte Fierens, Frank E Rademakers, Peter Bossuyt

|Sep 29, 2025
Development and validation of the FR-QoL-29-Dutch (Flemish) Questionnaire and assessment of clinical factors associated with food-related quality of life in a Belgian inflammatory bowel disease population: a cross-sectional study.

Judith Wellens, Livia Guadagnoli, Julie Vanderstappen

|Jul 11, 2025
Real-World Clinical Effectiveness and Safety of Vedolizumab and Ustekinumab in Biologic-Naïve Patients With Early or Late Crohn's Disease: Results From the EVOLVE Expansion Study.

Britt Christensen, Michael Scharl, Brian Bressler

Pageof 11

Frequent Collaborators

26 joint publications

Bram Verstockt

24 joint publications

Séverine Vermeire

9 joint publications

João Sabino

6 joint publications

Erwin Dreesen